AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have signed a clinical trial collaboration agreement with Summit Therapeutics (Nasdaq: SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with Summit's ivonescimab across multiple tumor types, including lung and breast cancers.

The companies plan to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Under the agreement, each company will contribute its respective compound for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo. All three companies will share trial costs while retaining development and commercial rights to their respective medicines.

Datroway is a TROP2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca. It is currently approved in more than 30 countries for unresectable or metastatic TNBC and in more than 45 countries for HR-positive, HER2-negative breast cancer. It also holds approval in Brazil, Russia, Singapore, and the U.S. for certain non-small cell lung cancer patients.

Ivonescimab is a bispecific antibody that combines PD-1 blockade with anti-angiogenesis effects through VEGF inhibition in a single molecule.

"We are encouraged by the opportunity to explore ivonescimab in combination with Datroway to potentially deliver clinically meaningful benefit to patients," said John Tsai, MD, Global Head, R&D, Daiichi Sankyo.

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics, said the collaboration "represents an important expansion of Summit's global development program into breast cancer and a path for additional solid tumor settings."

Datroway is currently being evaluated in more than 20 clinical trials across multiple cancer types, including eight phase 3 trials in lung cancer and five phase 3 trials in breast cancer.

You May Also Be Interested In

• Trump: just concluded a highly successful discussion with president Vladimir Putin
• Pomdoctor faces Nasdaq delisting over minimum bid price failure
• Starlink receives authorization to operate in Venezuela